Genova Announces Early Detection for Alzheimer’s

Stock.adobe.com

Genova Diagnostics launched a new Alzheimer’s blood test that utilizes the P-Tau217 biomarker.¹ The test, named the Alzheimer’s Assessment, should allow for more accurate early detection of the disease. Neurocode, a neurological diagnostics and research company, worked in partnership with Genova on the test.

The test has the potential to identify the disease years before symptoms appear. Due to the nature of the disease and the damage that it causes, catching it prior to the appearance of symptoms can significantly improve the quality of life for people suffering from it.

In a press release, Genova Diagnostics CEO Jeff Ledford said, “Our partnership with Neurocode has enabled us to bring this state-of-the-art Alzheimer's Assessment to the market. By combining our expertise in laboratory services with Neurocode's cutting-edge neurological research, we can offer a test that significantly impacts the early diagnosis and treatment of Alzheimer's disease. This is a significant step forward in our mission to provide innovative, science-based diagnostic services that improve patient outcomes."

Neurocode’s chief science officer added, “Neurocode is honored to work with Genova in the clinical launch of Alzpath pTau217 assay for accurately detecting amyloid pathology of Alzheimer's type. Neurocode has performed the most extensive clinical validation in the industry, making our test very trustworthy even for people with very minor memory issues."

Neurocode’s CEO also said, “Offering the pTau217 biomarker through partnership with Genova Diagnostics gives drastic accessibility to a larger segment of people that can now monitor amyloid activity in their brains with a simple blood draw. Neurocode is very excited to realize this potential."

This is the latest early-detection test that Geneva has co-developed. In July, the company announced that it had partnered with Seraphina Therapeutics to develop a test to assess the pentadecanoic acid.² This could allow for the detection of Cellular Fragility Syndrome.

In a press release issued at the time, Ledford said, “Genova Diagnostics is excited to be collaborating with Seraphina Therapeutics on this unique project. Dr. Venn-Watson's research has brought tremendous excitement and attention to the importance of individual fatty acids in the spectrum of human health."

He continued, “Genova is dedicated to advancing health through innovative partnerships and scientific research. The Fatty15 Test exemplifies our commitment to expanding the availability of essential testing and promoting optimal health."

In June of 2020, Genova also announced a new at-home test for a variety of nutritional data points that does not require a blood draw.³

Geneva’s chief scientific officer Dr. Amy Peace Brewer said, “The study of metabolomics is all encompassing - organic acids, amino acids, fatty acids, stool metabolites, hormone metabolites, and more. Genova Diagnostics has been an industry leader in metabolomic testing for decades. Our newest profile, Metabolomix+, is a modular profile allowing clinicians to build their own version of metabolomic testing based on clinical need. As an added benefit, it can be collected in the comfort of the patient's home, at their convenience."

Sources

Genova Diagnostics Partners with Neurocode to Launch Innovative Alzheimer's Assessment. Genova Diagnositcs, Inc. August 9, 2024. https://www.prnewswire.com/news-releases/genova-diagnostics-partners-with-neurocode-to-launch-innovative-alzheimers-assessment-302218441.html

Genova Diagnostics Launches At-home Fatty15 Test. Geneva Diagnostics, Inc. July 23, 2024. Accessed August 12, 2024. https://www.prnewswire.com/news-releases/genova-diagnostics-launches-at-home-fatty15-test-302203956.html

New Noninvasive Nutritional Testing with Metabolomix+. Geneva Diagnositcs, Inc. June 24, 2020. Accessed August 12, 2024. https://www.prnewswire.com/news-releases/new-noninvasive-nutritional-testing-with-metabolomix-301082912.html